吉非替尼单药治疗终末期肺腺癌患者的临床观察  

Clinical observation on the treatment of advanced non-small cell lung cancer with gefitinib

作　　者：符炜[1] 顾丽梅[1] 钱屹崟[1] 吴剑平[1] 

机构地区：[1]常熟市第一人民医院肿瘤科,215500

出　　处：《江苏医药》2010年第17期2013-2015,共3页Jiangsu Medical Journal

摘　　要：目的探讨吉非替尼(gefitinib)单药治疗终末期肺腺癌的疗效。方法 36例终末期肺腺癌患者(治疗组)口服吉非替尼250mg/d,直至病情进展或出现不可耐受的毒副反应;同期的35例(对照组)终末期肺腺癌患者接受最佳支持治疗。比较近期疗效、生活质量、中位无疾病进展时间(MTTP)、中位生存期(MST)及毒副反应。结果治疗组36例中无完全缓解(CR),有效率(RR)为61.11%(22/36),疾病控制率(DCR)为77.78%(28/36);疾病相关症状改善率为77.78%(28/36);MTTP8.92个月;MST14.8个月;主要的毒副反应为Ⅰ～Ⅱ度皮疹和腹泻,可耐受。对照组有6例仅稳定了1～2个月,2个月后35例均病情进展,MST4.26个月。结论吉非替尼治疗临床选择的终末期肺腺癌有较好的疗效和安全性,延长生存期。Objective To evaluate the efficacy and safety of gefitinib in the treatment of advanced non-small cell lung cancer（NSCLC）.Methods Gefitinib 250mg/d was given in 36 advanced NSCLC patients（group A）until disease progression or intolerable toxicity occurring.The best supportive care was used in 35 advanced NSCLC patients（group B）as control.The outcomes and side effects were recorded.Results In group A,no complete remission（CR）was seen,the effective rate（RR）was 61.11%（22/36）,disease control rate（DCR）was 77.78%（28/36）,remission rate of disease-related symptoms was 77.78%（28/36）,median time to tumor progression（MTTP）was 8.92 months,the median overall survival time（MST）was 14.8 months.The main side effects of gefitinib were rash and diarrhea,which were well acceptable.In group B,six patients showed stable disease for one to two months and the condition was deteriorated thenafter with a MST of 4.26 months.Conclusion Gefitinib is effective and safe in treating advanced non-small cell lung cancer and prolonging survival time.

关 键 词：非小细胞肺癌 吉非替尼 

分 类 号：R734[医药卫生—肿瘤]